Loading patent…
AssigneeWisconsin Alumni Research Foundation
InventorsEric Schmuck, Amish Raval
Estimating the term…
Compositions and methods using an engineered cardiac fibroblast-derived 3-dimensional extracellular matrix (ECM) are disclosed. The ECM includes the structural proteins fibronectin, collagen type I, collagen type III, and elastin, and from 60% to 90% of the structural proteins present in the engineered extracellular matrix are fibronectin. The compositions, which can be used to treat cardiac disease or ischemic disease or injury, are injectable compositions, where the ECM is diced into small fragments or lyophilized into a powder. The disclosed methods include a method of treating ischemic disease or injury by contacting a cell free patch made from the ECM with the injured tissue, without the concomitant delivery of therapeutic cells, and a method of treating ischemic limb injury by contacting a patch, either by itself or seeded with therapeutic cells, with the injured limb tissue.
An injectable composition for treating cardiac disease, cardiac injury, or ischemic injury, comprising:
The composition of claim, 10, wherein the one or more exogenous non-cellular therapeutic agents include one or more growth factors.
A method for treating a subject having an ischemic disease or injury, comprising contacting a tissue of the subject that is exhibiting an ischemic injury with a cell free engineered cardiac fibroblast cell-derived extracellular matrix having a thickness of 20-500 μm comprising the structural proteins fibronectin, collagen type I, collagen type III, and elastin, wherein from 60% to 90% of the structural proteins present in the engineered extracellular matrix are fibronectin, and wherein no cells are seeded onto the engineered cardiac fibroblast cell-derived extracellular matrix,
A method for treating a subject having an ischemic limb injury, comprising contacting a tissue of the subject that is exhibiting an ischemic limb injury with an engineered cardiac fibroblast cell-derived extracellular matrix having a thickness of 20-500 μm comprising the structural proteins fibronectin, collagen type I, collagen type III, and elastin, wherein from 60% to 90% of the structural proteins present in the engineered extracellular matrix are fibronectin,
Dependencies are inferred from the claim text.